Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock

Stock Information for Ocugen, Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Ocugen, Inc.

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial
Attention Ocugen, Inc. (OCGN) Shareholders: Grabar Law Office Investigates Claims on Your Behalf
Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa
Ocugen, Inc. (OCGN) Shareholder Notice: Grabar Law Office Investigates Claims on Your Behalf
Ocugen to Participate in a Fireside Chat at Chardan's 8th Annual Genetic Medicines Conference
Shareholder Alert: Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Ocugen, Inc. (OCGN)
Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm
GRABAR LAW OFFICE INVESTIGATES CLAIMS ON BEHALF OF LONG-TERM SHAREHOLDERS OF OCUGEN, INC. (NASDAQ: OCGN)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.